<DOC>
	<DOCNO>NCT00387907</DOCNO>
	<brief_summary>The purpose study evaluate anti-tumor activity combination experimental drug ( larotaxel ) combine Herceptin® patient advance breast cancer . Anti-tumor activity determine look change tumor size CT MRI scan . Additional goal study look patient safety , determine long study drug ( larotaxel Herceptin® ) stay patient 's body effect study medication may , find long patient remain cancer free study treatment .</brief_summary>
	<brief_title>Study Larotaxel Combination With Weekly Herceptin® Patients With HER2 Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Diagnosis breast cancer Evidence cancer spread beyond original location come back remove surgery No one prior treatment advanced disease Her2 positive status Adequate liver kidney function No remain severe harmful effect prior treatment Certain heart condition Pregnant Women History another cancer except skin cancer cervical cancer Taking treatment cancer time enter trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Herceptin</keyword>
	<keyword>Taxane</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>